Skip to Content

Novo Nordisk A/S ADR

View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation

Novo Nordisk's Massive GLP-1 Growth Reflects the Firm's Wide Moat in Cardiometabolic Diseases

Business Strategy and Outlook

As a pioneer in diabetes care, Novo has been in the business for over 85 years and claims 34% of the $50 billion-plus diabetes treatment market and roughly half of the more than $15 billion insulin market. Diabetes' prevalence is expected to soar in coming decades as a result of an increasingly overweight and aging population, and we expect Novo to maintain its wide moat as it continues to dominate in diabetes and obesity therapy innovation.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of NVO so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center